Pharma courses

Pharma Admission

pharma courses

pharma admission

About Author:
Kambham Venkateswarlu
Graduate Student
Sri Lakshmi Narasimha College of Pharmacy,
Palluru, Chittoor District, Andhra Pradesh-517132, India.

This is an inherited arrhythmia that causes the bottom chambers of the heart (the ventricles) to beat so fast that they can prevent the blood from circulating efficiently in the body. When this situation occurs (called ventricular fibrillation), the individual will faint and may die in a few minutes if the heart is not reset. While this is a disease that usually affects people in their 30's, it has actually been described at all ages. So it is important to screen everybody in a family. Not everybody who has the disease will have arrhythmias. However, we cannot know yet who will be OK and who will have problems. If you have had fainting spells related to Brugada syndrome, our experience indicates that you are at very high risk of having them again.

Reference Id: PHARMATUTOR-ART-1602

The Brugada syndrome is a genetic disease that is characterised by abnormal electrocardiogram (ECG) findings and an increased risk of sudden cardiac death. It is named by the Spanish/Belgian cardiologists Pedro Brugada and Josep Brugada. It is the major cause of sudden unexplained death syndrome (SUDS), and is the most common cause of sudden death in young men without known underlying cardiac disease in Thailand and Laos.

Although the ECG findings of Brugada syndrome were first reported among survivors of cardiac arrest in 1989, it was only in 1992 that the Brugada brothers recognized it as a distinct clinical entity, causing sudden death by causing ventricular fibrillation (a lethal arrhythmia) in the heart.

The first patient with this syndrome was seen in 1986. The patient was a three year old boy from Poland. He had presented multiple episodes of loss of consciousness and had been resuscitated multiple times by his father. The child's sister had died suddenly at age two after multiple episodes of aborted sudden death. When she died, she was receiving amiodarone and had a ventricular pacemaker implanted. The electrocardiograms of the two siblings were very similar and abnormal (picture 3). The identification of two additional patients resulted in the presentation of the preliminary data at the meeting of the North American Society of Pacing and Electrophysiology (NASPE) in 1991. The first paper including 8 patients was published in 1992. Since then, there has been an exponential increase in the number of patients recognized all over the world. The recent discovery of the genetic abnormalities linked to this syndrome, points to it being a primary electrical disease, providing an important first step in the prevention and effective treatment of this form of sudden death in patients with a structurally normal heart.

Several authors have previously reported electrocardiograms similar to the one presented in For the most part, these were considered variants of the normal electrocardiogram and no definitive link to sudden death was established.

In the 1980's the CDC (Center for Disease Control) in Atlanta, reported an abnormally high incidence of sudden death in young immigrants from Southeast Asia. Interestingly, the natives knew the problem for many decades. In the Northeast of Thailand, this form of death was known as Lai Tai (death during sleep). The indigenous believe that the young men died during sleep because widow ghosts came to take them away. Many young men actually dress still as women to go to sleep at night - a practice carried out for more than 70 years - with the hope that it would mislead the widow ghost, who then would not take these young men. In Philippines the phenomenon was known as Bangungut (scream followed by sudden death during sleep) and in Japan as Pokkuri (unexpected sudden death at night). The incidence of this form of sudden death has been estimated between 26 and 38 cases per 100,000 inhabitants per year. In Laos it may cause 1 sudden death per 1.000 inhabitants per year. Unexpected sudden death is the most common cause of natural death in young Thai people. It has been only recently discovered that many of these patients suffer the Brugada syndrome. The higher prevalence of this syndrome in some areas can be explained by its genetic transmission.

This syndrome is genetically determined. Approximately 60% of patients with (aborted) sudden death with the typical electrocardiogram have a family history of sudden death, or have family members with the same electrocardiographic abnormalities. There are also sporadic cases who are probably the patients with a de novo mutation in the family. The pattern of transmission is autosomic dominant. There is a predominance of affected males. In Thailand the disease almost exclusively affects males. The explanation to this predominance is not clear but it is possibly related to some modifier genes. Several mutations linked to this syndrome affecting the gene SCN5A which encodes for the cardiac sodium channel have been described. Some of the families studied do not present these mutations in this gene, indicating that other genetic defects will be found and that this is a genetically heterogeneous disease.

The mutations affecting patients in Japan and South Asia are still unknown. The in vitro studies show that the mutant channel has altered function, with a loss of sodium current that is temperature dependent. The loss of current leaves Ito unopposed, creating heterogeneity of refractory periods and a perfect substrate for arrhythmias based on phase 2 re-entry.

Because the syndrome has been identified only recently, it is difficult to ascertain its incidence and distribution in the world. When we analyze the data from the different publications, the disease is responsible for 4 to 12 % of unexpected sudden deaths, and for up to 50% of all sudden death in patients with an apparently normal heart. The incidence may even be higher in the younger population. Indeed, this syndrome is the most common cause of sudden death in individuals younger than 50 in South Asia with no underlying cardiac disease. It is important to stress that the physician plays an important role in the identification of the syndrome to estimate its real prevalence. This syndrome is possibly more prevalent, but the magnitude of it has yet to be determined. The difficulty to estimate the incidence and prevalence of the disease becomes more complicated as we unravel the syndrome and some of its peculiar characteristics. It is a syndrome that can present with a typical electrocardiogram but in some other cases the patient can present concealed forms or intermittent forms, meaning that the electrocardiogram is normal at certain times. The electrocardiogram of the syndrome may be unmasked by the administration of ajmaline, flecainide or procainamide. The pharmacologic test is so specific, that it is recommended in all patients who present with a history of syncope of unknown origin or ventricular fibrillation of unknown cause. Unfortunately, these tests are not applied routinely. Without a doubt this is one of the reasons why the prevalence of the disease probably is underestimated. Recent data from France and Japan show a prevalence of 1 per 1000 electrocardiograms compatible with the syndrome in the normal adult population.



Subscribe to Pharmatutor Alerts by Email